Rockey Don C
Division of Digestive and Liver Diseases, Department of Internal Medicine, The University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA.
Clin Liver Dis. 2008 Nov;12(4):939-62, xi. doi: 10.1016/j.cld.2008.07.011.
Chronic injury results in a wound healing response that eventually leads to fibrosis. The response is generalized, with features common among multiple organ systems. In the liver, various different types of injury lead to fibrogenesis, implying a common pathogenesis. Although several specific therapies for patients who have different liver diseases have been successfully developed, including antiviral therapies for those who have hepatitis B and hepatitis C virus infection, specific and effective antifibrotic therapy remains elusive. Over the past 2 decades, great advances in the understanding of fibrosis have been made and multiple mechanisms underlying hepatic fibrogenesis uncovered. Elucidation of these mechanisms has been of fundamental importance in highlighting novel potential therapies. Preclinical studies have indicated several putative therapies that might abrogate fibrogenesis. This article emphasizes mechanisms underlying fibrogenesis and reviews available and future therapeutics.
慢性损伤会引发伤口愈合反应，最终导致纤维化。这种反应具有普遍性，在多个器官系统中都有共同特征。在肝脏中，各种不同类型的损伤都会导致肝纤维化，这意味着存在共同的发病机制。尽管已经成功开发了几种针对不同肝病患者的特异性疗法，包括针对乙型和丙型肝炎病毒感染患者的抗病毒疗法，但特异性和有效的抗纤维化疗法仍然难以捉摸。在过去20年里，人们对纤维化的认识取得了巨大进展，揭示了肝纤维化发生的多种潜在机制。对这些机制的阐明对于发现新的潜在治疗方法至关重要。临床前研究已经表明了几种可能消除纤维化的假定疗法。本文重点介绍纤维化发生的机制，并综述现有的和未来的治疗方法。
